Table 1 Baseline clinical-pathological characteristics of patients included in the study
Median age | 69 years (48–83 years) |
|---|---|
Sex: | |
Male | 37 (84.00%) |
Female | 7 (16.00%) |
ECOG PS: | |
0 | 12 (27.30%) |
1 | 19 (43.20%) |
2 | 13 (29.50%) |
Smoking status: | |
Never smoker | 2 (4.55%) |
Previous smoker | 31 (70.45%) |
Current smoker | 11 (25.00%) |
Comorbidities: | |
Hypertension | 31 (70.45%) |
Dyslipidemia | 17 (38.64%) |
Diabetes | 11 (25.00%) |
COPD | 8 (18.18%) |
HF | 6 (13.64%) |
CRF | 0 (0.00%) |
Immune disorder | 0 (0.00%) |
Histology: | |
Adenocarcinoma | 25 (58.14%) |
Squamous cell carcinoma | 18 (41.86%) |
Asymptomatic brain metastases: | |
Yes | 8 (18.60%) |
No | 35 (81.40%) |
PD-L1 TPS: | |
Available | 23 (52.27%) |
− 0% | 4 (17.39%) |
- ≥ 1% < 50% | 19 (82.61%) |
Not Available | 21 (47.73%) |
Type of mAb: | |
Nivolumab | 28 (63.64%) |
Pembrolizumab | 9 (20.45%) |
Atezolizumab | 7 (15.91%) |
Type of response: | |
CR | 2 (4.55%) |
PR | 8 (18.18%) |
SD | 9 (20.45%) |
PD | 25 (56.82%) |
ORR | 10 (22.73%) |
Survival outcomes: | |
Median follow-up | 41.46 months (12.56–53.20 months) |
Median PFS | 3.52 months |
Median OS | 8.53 months |